Reviva Pharmaceuticals Holdi · Q4 2021 earnings

Briefing

Reported financial results for the full year ended December 31, 2021, and summarized recent business highlights.

Reviva Pharmaceuticals reported a net loss of $8.5 million, or $0.58 per share, for the year ended December 31, 2021. The company's cash totaled approximately $29.7 million as of December 31, 2021.

• First patient dosed in pivotal Phase 3 study and long-term safety trial evaluating brilaroxazine for the treatment of schizophrenia (Jan 2022).
• Joined the Russell Microcap® Index as part of the Russel U.S. Indexes annual reconstitution (Jun 2021).
• Raised Gross Proceeds of $34.5 Million in Public Offering of Common Stock and Warrants (May 2021).
• Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia anticipated in mid-2023.

Headline financials

Revenue & EPS history

Reviva plans to prioritize near-term efforts and may initiate Phase 2a studies in neuropsychiatric indications, subject to the receipt of additional financing, potentially as early as 2H-2022. Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia anticipated in mid-2023. Pursue partnership opportunities for the development of our pipeline. Evaluate grant and other non-dilutive financing opportunities for our product candidates from Federal and State Healthcare Agencies and Foundations.